COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab.
作者信息
Förster-Ruhrmann Ulrike, Szczepek Agnieszka J, Bachert Claus, Olze Heidi
机构信息
Department of Otorhinolaryngology, Head and Neck Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt- Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Upper Airways Research Laboratory and Department of Oto-Rhino-Laryngology, Ghent University, Ghent, Belgium, Germany.
出版信息
J Allergy Clin Immunol. 2020 Jul;146(1):218-220.e2. doi: 10.1016/j.jaci.2020.05.005. Epub 2020 May 15.
Abstract
摘要
相似文献
1
COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab.在使用度普利尤单抗治疗期间，一名患有严重慢性鼻-鼻窦炎伴鼻息肉的患者感染了新冠病毒。
J Allergy Clin Immunol. 2020 Jul;146(1):218-220.e2. doi: 10.1016/j.jaci.2020.05.005. Epub 2020 May 15.
2
Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma.度普利尤单抗可改善患有鼻息肉和合并哮喘的慢性鼻-鼻窦炎患者的患者报告结局。
J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2447-2449.e2. doi: 10.1016/j.jaip.2019.03.023. Epub 2019 Mar 27.
3
Impact of dupilumab prescribing on utilization of medical and surgical therapies for chronic rhinosinusitis with nasal polyps.度普利尤单抗处方对慢性鼻-鼻窦炎伴鼻息肉患者医疗和手术治疗利用的影响。
Int Forum Allergy Rhinol. 2024 Jul;14(7):1249-1252. doi: 10.1002/alr.23325. Epub 2024 Jan 31.
4
The characterization of chronic rhinosinusitis in hospitalized patients with COVID-19.新冠病毒感染住院患者慢性鼻-鼻窦炎的特征
J Allergy Clin Immunol Pract. 2020 Nov-Dec;8(10):3597-3599.e2. doi: 10.1016/j.jaip.2020.09.013. Epub 2020 Sep 24.
5
Dupilumab Approved to Treat Chronic Rhinosinusitis with Nasal Polyposis.度普利尤单抗获批用于治疗伴有鼻息肉的慢性鼻-鼻窦炎。
Am J Nurs. 2019 Oct;119(10):21-22. doi: 10.1097/01.NAJ.0000586144.72896.a5.
6
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.瑞利珠单抗在伴有鼻息肉的慢性鼻-鼻窦炎并自我报告的嗜酸性粒细胞性哮喘患者亚组中的哮喘结局的影响。
J Allergy Clin Immunol Pract. 2019 Feb;7(2):589-596.e3. doi: 10.1016/j.jaip.2018.08.021. Epub 2018 Sep 5.
7
Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis.成人慢性鼻-鼻窦炎的当前和未来治疗选择：关注鼻息肉。
J Allergy Clin Immunol. 2015 Dec;136(6):1431-1440. doi: 10.1016/j.jaci.2015.10.010.
8
Management of chronic rhinosinusitis with steroid nasal irrigations: A viable nonsurgical alternative in the COVID-19 era.类固醇鼻腔冲洗治疗慢性鼻-鼻窦炎：COVID-19 时代一种可行的非手术替代方法。
Int Forum Allergy Rhinol. 2020 Sep;10(9):1108-1109. doi: 10.1002/alr.22646. Epub 2020 Jul 16.
9
Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps.度普利尤单抗对重度慢性鼻-鼻窦炎伴鼻息肉的快速和持续疗效。
Int Forum Allergy Rhinol. 2022 Jul;12(7):958-962. doi: 10.1002/alr.22944. Epub 2022 Jan 23.
10
The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps.生物制剂在慢性鼻-鼻窦炎伴鼻息肉中的作用。
Ear Nose Throat J. 2021 Jan;100(1):44-47. doi: 10.1177/0145561320964653. Epub 2020 Oct 9.
引用本文的文献
1
[SEPAR Recommendations for COVID-19 Vaccination in Patients With Respiratory Diseases].[呼吸系统疾病患者新冠病毒疫苗接种的SEPAR建议]
Open Respir Arch. 2021 Mar 22;3(2):100097. doi: 10.1016/j.opresp.2021.100097. eCollection 2021 Apr-Jun.
2
COVID-19 Clinical Features and Outcome in Italian Patients Treated with Biological Drugs Targeting Type 2 Inflammation.接受靶向2型炎症生物药物治疗的意大利患者的COVID-19临床特征与转归
Life (Basel). 2024 Mar 13;14(3):378. doi: 10.3390/life14030378.
3
The impact of chronic rhinosinusitis on COVID-19 risk and outcomes: A systematic review and meta-analysis.慢性鼻-鼻窦炎对 COVID-19 风险和结局的影响：系统评价和荟萃分析。
Front Immunol. 2023 Mar 29;14:1139031. doi: 10.3389/fimmu.2023.1139031. eCollection 2023.
4
Epidemiological Characteristics, Pathogenesis and Clinical Implications of Sinusitis in the Era of COVID-19: A Narrative Review.COVID-19时代鼻窦炎的流行病学特征、发病机制及临床意义：一项叙述性综述
J Asthma Allergy. 2023 Jan 27;16:201-211. doi: 10.2147/JAA.S398686. eCollection 2023.
5
COVID-19 and rhinological surgery.新型冠状病毒肺炎与鼻科手术
Oper Tech Otolayngol Head Neck Surg. 2022 Jun;33(2):103-111. doi: 10.1016/j.otot.2022.04.005. Epub 2022 Apr 28.
6
Chronic Rhinosinusitis and COVID-19.慢性鼻-鼻窦炎与 COVID-19。
J Allergy Clin Immunol Pract. 2022 Jun;10(6):1423-1432. doi: 10.1016/j.jaip.2022.03.003. Epub 2022 Mar 17.
7
Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians.SARS-CoV-2 大流行背景下慢性呼吸道疾病患者的风险评估：德国呼吸学会与德国胸科医师协会支持的立场声明。
Respiration. 2022;101(3):307-320. doi: 10.1159/000518896. Epub 2022 Jan 21.
8
Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome.抗2型炎症生物疗法对COVID-19临床病程及结局的影响
J Inflamm Res. 2021 Dec 14;14:6845-6853. doi: 10.2147/JIR.S345665. eCollection 2021.
9
Impact of COVID-19 on patients with atopic dermatitis.COVID-19 对特应性皮炎患者的影响。
Clin Dermatol. 2021 Nov-Dec;39(6):1083-1087. doi: 10.1016/j.clindermatol.2021.07.008. Epub 2021 Jul 17.
10
Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment-a population-based cohort study.患有特应性皮炎并接受度普利尤单抗治疗的患者罹患 COVID-19 及其并发症的风险：一项基于人群的队列研究。
Immunol Res. 2022 Feb;70(1):106-113. doi: 10.1007/s12026-021-09234-z. Epub 2021 Oct 13.
本文引用的文献
1
Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence.免疫抑制与刺激药物和新型冠状病毒肺炎之间的关联——当前证据的系统评价
Ecancermedicalscience. 2020 Mar 27;14:1022. doi: 10.3332/ecancer.2020.1022. eCollection 2020.
2
Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression.COVID-19 患者可能受益于持续的洛匹那韦联合治疗方案，而嗜酸性粒细胞的增加可能预测 COVID-19 进展的结果。
Int J Infect Dis. 2020 Jun;95:183-191. doi: 10.1016/j.ijid.2020.03.013. Epub 2020 Mar 12.
3
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.中国武汉 140 名 SARS-CoV-2 感染患者的临床特征。
Allergy. 2020 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27.
4
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.度普利尤单抗治疗伴有鼻息肉的重度慢性鼻-鼻窦炎患者的疗效和安全性（LIBERTY NP SINUS-24 和 LIBERTY NP SINUS-52）：两项多中心、随机、双盲、安慰剂对照、平行分组 3 期临床试验的结果。
Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19.
5
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).度普利尤单抗治疗中重度特应性皮炎的实验室安全性：三项III期试验（LIBERTY AD SOLO 1、LIBERTY AD SOLO 2、LIBERTY AD CHRONOS）的结果
Br J Dermatol. 2020 May;182(5):1120-1135. doi: 10.1111/bjd.18434. Epub 2019 Dec 1.
6
Glucocorticoids promote apoptosis of proinflammatory monocytes by inhibiting ERK activity.糖皮质激素通过抑制 ERK 活性促进促炎单核细胞凋亡。
Cell Death Dis. 2018 Feb 15;9(3):267. doi: 10.1038/s41419-018-0332-4.
7
Psychometric validity of the 22-item Sinonasal Outcome Test.22 项鼻-鼻窦结局测试的心理测量效度。
Clin Otolaryngol. 2009 Oct;34(5):447-54. doi: 10.1111/j.1749-4486.2009.01995.x.
8
T cell responses to whole SARS coronavirus in humans.人类对完整严重急性呼吸综合征冠状病毒的T细胞反应。
J Immunol. 2008 Oct 15;181(8):5490-500. doi: 10.4049/jimmunol.181.8.5490.
9
Development of the asthma control test: a survey for assessing asthma control.哮喘控制测试的开发：一项评估哮喘控制情况的调查
J Allergy Clin Immunol. 2004 Jan;113(1):59-65. doi: 10.1016/j.jaci.2003.09.008.
Zotero 插件